Pheochromocytoma in multiple endocrine neoplasia type 2: A prospective study

European Journal of Endocrinology

Volumn 144, Issue 1, 2001, Pages 37-44

  Nguyen, L ^a   Niccoli Sire, P ^a   Caron, P ^a   Bastie, D ^a   Maes, B ^a   Chabrier, G ^a   Chabre, O ^a   Rohmer, V ^a   Lecomte, P ^a   Henry, J F ^a   Conte Devolx, B ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CATECHOLAMINE; METADRENALIN; PENTAGASTRIN;

ADOLESCENT; ADRENAL GLAND; ADRENAL TUMOR; ADRENALECTOMY; ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER LOCALIZATION; CATECHOLAMINE URINE LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; FEMALE; GENETIC ANALYSIS; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE ADENOMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA;

EID: 0035151026     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1440037     Document Type: Article

References (42)

1. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease
2. Multiple endocrine neoplasia
3. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
4. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
5. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
6. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis
7. Pheochromocytoma in multiple endocrine neoplasia type 2A: A survey of 100 cases
8. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes
9. Pheochromocytoma in multiple endocrine neoplasia type 2: European study
10. Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 - Relevance of specific mutations in the RET proto-oncogene
11. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma
12. Création d'un groupe d'études des tumeurs à calcitonine
13. RET proto-oncogene mutations in the French MEN 2A and FMTC families
14. Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal anti-peptide antibodies
15. Diagnosis of medullary carcinoma of the thyroïd by calcitonin assay using monoclonal antibodies
16. Pentagastrin stimulation test and early diagnosis of medullary carcinoma using an immunoradiometric assay of calcitonin: Comparison with genetic screening in hereditary medullary thyroid carcinoma
17. Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and familial medullary thyroid carcinoma families
18. Biochemical tests for the diagnosis of pheochromocytoma: Urinary versus plasma determinations
19. Evolving concepts in the pathophysiology, diagnosis and treatment of pheochromocytomas
20. The urinary metanephrine-to-creatinine ratio for the diagnosis of pheochromocytoma
21. Overnight excretion of urinary catecholamines and metabolites in the detection of pheochromocytoma
22. Measurement of plasma methoxyamines for the diagnosis of pheochromocytoma
23. Plasma metanephrines in the diagnosis of pheochromocytomas
24. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors
25. Plasma normetanephrine and metanephrine for detecting pheochromocytomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2
26. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: Comparison with CT and MRI
27. Incidentally discovered adrenal masses
28. Effectiveness and limits of preoperative imaging studies for the localization of phaeochromocytomas and paragangliomas: A review of 282 cases
29. A comparison of laparoscopic and open adrenalectomy
30. Is laparoscopic adrenalectomy indicated for pheochromocytomas?
31. Etude comparative entre la surrénalectomie laparoscopique et conventionnelle dans les pheochromocytomas
32. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma
33. Subtotal adrenalectomy for pheochromocytoma in Multiple Endocrine Neoplasia type 2A
34. Adrenal-sparing surgery for pheochromocytoma
35. Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma
36. Complications after bilateral adrenalectomy for phaeochromocytoma in multiple endocrine neoplasia type 2 - A plea to conserve adrenal function
37. Management of hereditary pheochromocytoma in von Hippel-Lindau kindreds with partial adrenalectomy
38. Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas
39. Germline mutation of RET codon 883 in two cases of de novo MEN 2B
40. A new hot spot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A
41. Adrenal and extra-adrenal phaeochromocytoma in a family with germline RET V804L mutation
42. Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: Result in 71 thyroidectomized patients